South Korea's health insurance is due to cover four more medicines and expand one existing listing to adults on November 1, 2026. The Ministry of Health and Welfare announced the measures after review by the Health Insurance Policy Deliberation Committee in a release published October 29. As of October 30, the effective date is still ahead. The five changes are not five entirely new listings: Crysvita already had coverage for children, and its expansion concerns adults. A named drug in a release is not a guarantee of eligibility or a specific co-payment for every patient.
Match the product to the stated patient group
| Medicine (Korean product name) | Change and condition described in the ministry release |
|---|---|
| Crysvita injection (크리스비타주사액) | Coverage expands from children to adults for hypophosphatemic rickets and osteomalacia |
| Oxlumo injection (옥스루모주) | New coverage for primary hyperoxaluria type 1 |
| Spravato nasal spray (스프라바토나잘스프레이) | New coverage for moderate or more severe major depressive disorder not responding to at least two different antidepressants, described as treatment-resistant depression |
| Xcopri tablets (엑스코프리정) | New coverage for refractory epilepsy where existing medicines have not controlled seizures |
| Tibsovo tablets (팁소보정) | New coverage for IDH1 mutation-positive locally advanced or metastatic cholangiocarcinoma (bile duct cancer) |
The original Korean-language PDF, pp. 1–3 explains that Crysvita was already reimbursed for children. The adult expansion addresses gaps for people whose treatment was interrupted on reaching adulthood or who developed symptoms as adults. Saying all five products have just gained coverage for the first time would miss that distinction.
The remaining indications are also specific. Oxlumo concerns type 1 primary hyperoxaluria, not every condition with excess oxalate. Spravato's description involves a major depressive disorder of at least moderate severity and an inadequate response to two or more different antidepressants; a depression diagnosis alone does not establish that history. Xcopri's description concerns seizures not controlled by existing medicines. Tibsovo's description requires both an IDH1-positive mutation and locally advanced or metastatic bile duct cancer. Ask the treating team to interpret your test results and treatment record; do not make medication changes on the basis of this article.
A co-pay example is not a personal bill
The ministry expects coverage to ease patients' financial burden. A footnote gives 10% for rare-disease patients and 5% for cancer patients, among other examples, as patient shares of treatment-drug costs. It does not establish that every user of these five drugs, or every component of every hospital bill, will pay exactly 5% or 10%. Whether your treatment meets the detailed reimbursement rules, any applicable special co-payment arrangement, and costs for visits and tests must be checked in your own case.
The release describes disease groups and anticipated benefits; it does not by itself verify every detailed reimbursement criterion, duration of treatment, hospital stock or an individual's prescription decision. Its November 1 effective date is not an announcement that previously paid costs will automatically be refunded.
Three questions for your clinical team
-
Diagnosis and tests: Do my diagnosis, disease subtype, stage and, where relevant, IDH1 mutation result fit the announced group for this medicine?
-
Treatment history and timing: How do my previous medicines and responses relate to the actual reimbursement criteria and the date applicable to my treatment?
-
Expected costs: What would my drug, visit and testing costs be, and is a special co-payment program applicable to me?
Do not stop or switch treatment without your clinician. This is a guide to the scope of the ministry announcement, not medical advice, a prescription, or an individualized insurance determination.
Korean companion on Naver
About the Author
Life Mokcha's editorial team distinguishes the announcement's effective date, patient groups and example co-pay rates from an individual coverage decision.
